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LEARNING OBJECTIVES
After completing this course, the reader will be able to:
1. Describe the type of patient with soft tissue sarcoma most likely to benefit from adjuvant chemotherapy.
2. Select the chemotherapy regimen most likely to benefit a patient with high-risk soft tissue sarcoma.
3. Evaluate the impact of adjuvant chemotherapy on risk of soft tissue sarcoma recurrence analyzed in the sarcoma
meta-analyses.
This article is available for continuing medical education credit at CME.TheOncologist.com.CME
ABSTRACT
Soft tissue sarcoma is a malignant connective tissue
tumor that may arise anywhere in the body and from
diverse mesenchymal elements. Its incidence is approx-
imately 30 per million persons. The majority of patients
with soft tissue sarcoma present with potentially life-
threatening disease, and complete resection to obtain
specimen margins free of tumor and radiation offer the
best chance for local disease control. The risk of relapse
and death from disease rises with increasing tumor
stage, grade, and size. Adjuvant chemotherapy has been
studied as a means to decrease the risk for disease re-
currence in patients with localized soft tissue sarcoma at
diagnosis, but the majority of trials reported on have
been hampered by patient heterogeneity, low patient ac-
crual, and short follow-up. Meta-analysis and reviews of
institutional large series, in efforts to overcome some of
the limitations, suggest that doxorubicin with ifos-
famide reduces the risk for sarcoma recurrence and
death in selected patients with high-grade, large, and
chemotherapy-sensitive sarcoma subtypes to a clinically
meaningful degree. In multiple analyses, patients with
high-risk soft tissue sarcoma treated with chemother-
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apy have a >10% absolute lower risk for disease recur-
rence and longer disease-specific survival than patients
treated without chemotherapy. In the absence of con-
clusive results from an adequately powered, random-
ized, controlled clinical trial, the available data support
the use of chemotherapy in the management of high-
risk, localized, soft tissue sarcoma. The Oncologist 2009;
14:1003–1012
INTRODUCTION
Is there reasonable medical justification for offering pa-
tients diagnosed with high-risk soft tissue sarcoma adjuvant
chemotherapy? This question has been debated for 20
years, with many authors concluding that study results and
analyses are inconclusive because of faulty study design,
inadequate statistical power resulting from small study size,
short follow-up, bias from enrollment of patients with
lower-risk sarcoma, and/or poor quality of data. Herein, we
argue that sufficient evidence exists to recommend chemo-
therapy to selected patients diagnosed with high-risk, local-
ized soft tissue sarcoma as a maneuver to decrease the risk
for recurrence and early death from disease. We do not re-
view clinical management of the pediatric rhabdomyosar-
comas (alveolar and embryonal) and extraskeletal Ewing’s
family of tumors, for which chemotherapy is a recognized
vital component of appropriate care. Gastrointestinal stro-
mal tumors, a sarcoma of the gastrointestinal tract with
unique biology rendering the tumor susceptible to growth
inhibition by receptor tyrosine kinase inhibition and now
managed differently than most other soft tissue sarcomas,
are not discussed herein.
Clinical management of patients with soft tissue sar-
coma is complicated by the large heterogeneity of the nat-
ural history of the disease. More than 50 subtypes of soft
tissue tumors are recognized in the World Health Organi-
zation classification of tumors of soft tissue [1]. Sarcomas
may arise anywhere in the body; therefore, multidisci-
plinary management requires broad expertise in surgical,
orthopedic, medical, and radiation oncology. Patient out-
comes are likely influenced by the level of experience of the
treating physicians in managing sarcomas; patients treated
at centers with a special emphasis in sarcoma management
seem to have a lower risk for disease recurrence and longer
survival [2]. We know that certain subtypes, for example,
alveolar soft part sarcoma and clear cell sarcoma, have pro-
tracted clinical courses and/or relative resistance to tradi-
tional cytotoxic chemotherapy. In addition, recent advances
in the knowledge of sarcoma pathophysiology and diagno-
sis, such as the identification of gastrointestinal stromal
tumor as a distinct entity from gastrointestinal leiomyosar-
coma, has likely changed the population of patients studied
over time in clinical trials of adjuvant chemotherapy and in-
fluenced the results. Cure rates may be overestimated by in-
clusion of subtypes such as synovial sarcoma that can recur
10 years after definitive treatment, because the mean
length of follow-up in many studies is 10 years. Thus, het-
erogeneity of disease and study populations heavily bias
broad conclusions of chemotherapy benefit for patients
with soft tissue sarcoma.
Over 10,000 people are diagnosed with soft tissue sar-
coma in the U.S. each year and about 40%–50% die from
the malignancy [3, 4]. More than half of the patients with
soft tissue sarcoma have localized disease at the time of di-
agnosis. High tumor grade, large tumor size, and tumor in-
volvement through or below the fascia are well established
prognostic factors for disease recurrence and death after de-
finitive local control of limited soft tissue sarcoma (Table 1)
[5–7]. More than one half of the patients with high-grade
soft tissue sarcomas 10 cm involving deep structures de-
velop metastasis, usually involving the lungs, after local
therapy to the primary disease site, and the majority of pa-
tients with distant relapse die from their disease [8]. The im-
petus for continued study of adjuvant therapy for soft tissue
sarcoma stems from the high rate of fatality from relapsed
disease and greater impact on society, because younger in-
dividuals are disproportionately more affected than with
epithelial cancer.
EARLY ADJUVANT CHEMOTHERAPY
SARCOMA STUDIES
Doxorubicin was identified as an active anticancer agent in
patients with advanced soft tissue sarcoma in the 1970s [9,
10]. Ifosfamide added to doxorubicin demonstrated a
higher objective response rate of advanced/metastatic sar-
coma than doxorubicin alone and is considered a contem-
porary combination chemotherapy for soft tissue sarcoma
[11].
Rosenberg and colleagues at the National Cancer Insti-
tute performed a randomized trial between 1977 and 1981
of adjuvant doxorubicin, cyclophosphamide, and metho-
trexate in 65 patients with high-grade soft tissue sarcoma of
the extremity [12]. There was an imbalance in sarcoma sub-
types randomized to the chemotherapy versus “control”
arms and the median follow-up time of about 2 years at the
time of the report was short; however, significantly fewer
patients who received chemotherapy had a sarcoma relapse
(three versus nine) and death from disease (one versus
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four). This early randomized trial helped establish an inter-
est in the study of adjuvant chemotherapy in soft tissue sar-
coma. Other small studies have also suggested a benefit
from adjuvant chemotherapy [13, 14]. But, relapse and/or
survival benefit from adjuvant chemotherapy was not dem-
onstrated in other trials [15]. The relative infrequency of
sarcoma has hampered the ability to accrue a large number
of patients with uniform prognostic features to enable the
detection of a small but clinically meaningful improvement
in survival from adjuvant therapy.
META-ANALYSIS OF ADJUVANT CHEMOTHERAPY
IN SARCOMA
Meta-analyses of multiple studies have been performed and
reported in an effort to overcome some of the statistical lim-
itations of trials with small numbers of patients [16, 17].
The Sarcoma Meta-Analysis Collaboration (SMAC) pub-
lished, in 1997, the finding of a significant benefit from ad-
juvant doxorubicin-based chemotherapy in time to local
and distant recurrence and recurrence free-survival in pa-
tients with localized soft tissue sarcoma [18]. Those authors
reported a trend toward a higher overall survival rate in pa-
tients receiving chemotherapy, with an absolute benefit of
4% (7% for patients with extremity sarcoma) at 10 years,
representing a possible survival improvement from 50% to
54% over chemotherapy. Approximately 60% of the pa-
tients included in the meta-analysis had sarcoma localized
in an extremity. The effort was unique to previous meta-
analyses of sarcoma adjuvant therapy in that updated indi-
vidual patient data from 1,568 participants randomized to
adjuvant chemotherapy or no chemotherapy after definitive
local control in one of 14 trials was collected from primary
trial investigators and combined into a central database for
time-to-event analysis. Patients included in the analysis
were accrued to trials in the years 1973–1990; the median
follow-up was relatively long at 9.4 years, with a range of
5–17 years. The significance of the findings has been criti-
cized because of the inclusion of patients with low-grade
and small sarcomas, which may have diluted the benefit
from chemotherapy for more high-risk tumors, and lack of
information regarding tumor size, grade, and histology in
37%, 28%, and 18% of cases, respectively, despite the at-
tempt to collect primary data. Moreover, the planned dose
intensity of doxorubicin administered varied substantially
in the trials in the range of 200–550 mg/m2 and ifosfamide
was not part of the treatment regimen.
Pervaiz and colleagues recently expanded the SMAC
analysis by including the results of five contemporary ran-
domized controlled studies using an anthracycline and ifos-
famide that were not included in the original database [19].
Approximately 95% of the patients in the analysis had sar-
coma localized to an extremity or body wall, areas in which
complete resection of sarcoma with negative surgical mar-
gins is most likely achieved. The update found statistically
significant lower local, distant, and overall recurrence rates
and longer overall survival for patients receiving adjuvant
chemotherapy. The absolute reduction in the risk for recur-
rence was greater in the five pooled contemporary studies
than in the original analysis, and the authors suggested that
the effect may be a result of the inclusion of ifosfamide in
the adjuvant chemotherapy and/or intensification of the
anthracycline dose (Table 2). Analysis of the five trials that,
in total, randomized 200 patients to anthracycline and
ifosfamide and 200 to no chemotherapy suggests an ap-
proximate 10% lower absolute risk for distant recurrence
and death for the patients receiving chemotherapy. There
was a 30% versus 41% risk for death for patients receiving
versus not receiving an anthracycline and ifosfamide, re-
spectively, and a 40% versus 46% risk for death for patients
receiving chemotherapy versus no chemotherapy, respec-
tively, in the complete analysis. Data combined from all the
trials suggest that 10 and 17 patients would need to be
treated with adjuvant chemotherapy to prevent one recur-
Table 1. Five-year survival rates in patients with
localized soft tissue sarcoma
Variable
Metastasis-free
survival
Overall
survival
Tumor size
5 cm 82% 84%
5–10 cm 65% 76%
10 cm 56% 59%
Tumor grade
Low 92% 95%
High 63% 64%
Tumor depth
Superficial 89% 90%
Deep 64% 67%
AJCC stage
I 96%
II 78%
III 51%
Abbreviation: AJCC, American Joint Commission on
Cancer.
Adapted from Pisters PW, Leung DH, Woodruff J et al.
Analysis of prognostic factors in 1,041 patients with
localized soft tissue sarcomas of the extremities. J Clin
Oncol 1996;14:1679–1689 and Coindre JM, Terrier P,
Bui NB et al. Prognostic factors in adult patients with
locally controlled soft tissue sarcoma. A study of 546
patients from the French Federation of Cancer Centers
Sarcoma Group. J Clin Oncol 1996;14:869–877.
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rence and one death, respectively, from sarcoma. There are
weaknesses of the analysis, which include the use of pub-
lished aggregate data rather than individual patient data and
no attempt to obtain recent follow-up. The planned chemo-
therapy dose intensity varied among studies in the range of
150–300 mg/m2 for doxorubicin, 300–600 mg/m2 for epi-
rubicin, and 15–45 g/m2 for ifosfamide. Nevertheless, the
analysis provides compelling support for the use of adju-
vant chemotherapy, notably an anthracycline and ifos-
famide, in patients with high-risk localized soft tissue
sarcoma involving an extremity or trunk.
THE ITALIAN EXPERIENCE
A detailed discussion of the more recent randomized con-
trolled trials of adjuvant chemotherapy in soft tissue sar-
coma is helpful to interpret the meta-analyses. Frustaci and
colleagues in Italy performed a randomized trial of five cy-
cles of epirubicin (120 mg/m2 per cycle) and ifosfamide (9
g/m2 per cycle) given adjuvantly versus no chemotherapy
in 104 patients with high-grade, 5 cm, subfascial (Amer-
ican Joint Commission on Cancer [AJCC] stage III) soft tis-
sue sarcoma excised from an extremity or limb girdle [20].
Patients with locally recurrent tumors (18 patients) were el-
igible regardless of tumor size. Eligible subtypes included
fibrosarcoma, malignant fibrous histiocytoma, pleomor-
phic liposarcoma, leiomyosarcoma, synovial sarcoma, ma-
lignant peripheral nerve sheath tumor, pleomorphic
rhabdomyosarcoma, and angiosarcoma. Patients were strat-
ified by tumor size (10 cm versus 10 cm) and local re-
currence (no versus yes) and randomized after definitive
local therapy. Chemotherapy was started at a median inter-
val of 2 months after surgery. In the initial report, the me-
dian follow-up was 5 years. An intent-to-treat analysis
(though seven patients randomized to chemotherapy did not
receive treatment because four withdrew consent and me-
tastases were detected in the other three prior to chemother-
apy) detected a trend toward a higher rate of distant relapse-
free survival at 2 years, but not at 4 years, and a higher
overall survival rate at 4 years (69% survival rate in the che-
motherapy arm compared with a 50% survival rate in the
control group at 4 years).
An updated analysis of the Italian study after a median
follow-up of 90 months revealed a higher 5-year survival
rate for patients randomized to adjuvant chemotherapy and
a trend toward a longer median overall survival duration
[21]. However, excluding the seven patients in the treat-
ment arm who did not receive chemotherapy, 18 of 48 pa-
tients had died, whereas 28 of 51 patients in the control
group had died, and the difference reached significance de-
fined as p  .05. An unplanned subgroup analysis sug-
gested more benefit from chemotherapy for patients who
received 85% of the planned cumulative dose of chemo-
therapy than for patients receiving 85% of the planned
dose or no chemotherapy. The authors suggested that che-
motherapy dose intensity in adjuvant treatment of soft tis-
sue sarcoma may impact results.
Another randomized study of adjuvant epirubicin with
or without ifosfamide versus no chemotherapy in consecu-
tive patients with de novo nonmetastatic soft tissue sarcoma
was reported, by Petrioli et al. [22], to show a significantly
higher 5-year disease-free survival rate with chemotherapy.
That trial was not restricted to patients with sarcoma in an
extremity, but complete resection was required for study
participation. The large majority had malignant fibrous his-
tiocytoma (undifferentiated pleomorphic sarcoma), lipo-
sarcoma, or leiomyosarcoma, whereas 10% had another
subtype of sarcoma. More patients in the chemotherapy
than in the control arm had a sarcoma in an extremity or
grade II tumor, which may have biased the results in favor
of the chemotherapy arm. However, more of the sarcomas
in the control arm were 5 cm, which may have favored the
control arm. Approximately 50% of the patients in the trial
had tumors 5 cm. Chemotherapy-treated patients re-
ceived a mean dose of 95% of a planned 300 mg/m2 (75
mg/m2 per cycle for four cycles) of epirubicin. Nineteen of
45 patients who received chemotherapy had a mean dose of
95% of a planned 24 g/m2 (6 g/m2 per cycle for four cycles)
of ifosfamide concurrent with epirubicin. The disease-free
Table 2. Risk reductions from meta-analysis of adjuvant chemotherapy in soft tissue sarcoma
Treatment
Recurrence Survival
RR 95% CI ARR RR 95% CI ARR
Doxorubicin 0.69 0.56–0.86 9% 0.84 0.68–1.03 5%
Doxorubicin  ifosfamide 0.61 0.41–0.92 12% 0.56 0.36–0.85 11%
Abbreviations: ARR, absolute risk reduction; CI, confidence interval; RR, relative risk.
Adapted from Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of
adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573–581.
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and overall survival rates at 5 years for patients receiving
chemotherapy were 69% and 72%, respectively, and for
those not receiving chemotherapy were 44% and 47%, re-
spectively. For the group of patients accrued to the study
after the chemotherapy arm was amended to include
ifosfamide, the disease-free and overall survival rates at 5
years for patients receiving chemotherapy were 82% and
84%, respectively, and for those not receiving chemother-
apy were 46% and 57%, respectively. Unfortunately, the
single-institution trial took 10 years to accrue 88 patients
and was closed early because of the poor rate of accrual, and
thus was relatively underpowered.
OTHER RANDOMIZED TRIALS OF DOXORUBICIN
AND IFOSFAMIDE
Two other published studies of doxorubicin plus ifosfamide
as additional therapy for localized soft tissue sarcoma de-
serve mention. The Austrian Cooperative Soft Tissue Study
Group performed a relatively small randomized study of six
cycles of adjuvant doxorubicin, ifosfamide, and dacarba-
zine versus no chemotherapy in 59 patients with resected,
localized soft tissue sarcoma [23]. The planned doses of
doxorubicin and ifosfamide were 300 mg/m2 and 36 g/m2,
respectively. Twenty-five of the 31 patients randomized to
chemotherapy had a grade 3 tumor, whereas 16 of the 28
patients randomized to the control arm had grade 3 sar-
coma, favoring the control arm. After a short mean obser-
vation period of 41 months, seven of the 31 patients treated
with chemotherapy and 12 of the 28 patients in the control
arm suffered sarcoma relapse. The relapse-free survival
rate was significantly better in patients with grade 3 sarco-
mas treated with chemotherapy than in patients treated
without chemotherapy. Overall survival was not different
between the two arms, but the length of follow-up (mean,
41 months; range, 8 – 84 months) was likely too short to
show a difference.
Gortzak and colleagues reported on a randomized study
of preoperative doxorubicin and ifosfamide in patients with
“high-risk” sarcomas, suggesting no benefit from chemo-
therapy over surgery and radiation [24]. High-risk disease
was defined as sarcoma 8 cm of any grade and grade 2 or
3 sarcoma 8 cm locally recurrent or inadequately excised.
One hundred fifty patients were randomized and 134 were
eligible. The treatment arms were well balanced regarding
tumor size, location, and grade. Sarcoma was low grade in
8%. The objective response rate to preoperative treatment
was 28%. After a median follow-up interval 7 years, the
time to relapse and survival rates between the arms were
similar. Chemotherapy was limited to three cycles, result-
ing in a planned cumulative doxorubicin dose of 150 mg/m2
and ifosfamide dose of 15 g/m2, which are substantially
lower than doses used in adjuvant studies; thus, dose inten-
sity in this neoadjuvant trial could be considered inadequate
for systemic therapy.
NONRANDOMIZED INSTITUTIONAL EXPERIENCE
WITH ADJUVANT CHEMOTHERAPY FOR SOFT
TISSUE SARCOMA
An analysis of patients with 5 cm, high-grade, deep soft
tissue sarcoma localized to an extremity treated at Memo-
rial Sloan-Kettering Cancer Center or Dana-Farber Cancer
Institute suggested that adjuvant chemotherapy with doxo-
rubicin and ifosfamide resulted in longer disease-specific
survival (Table 3) [25]. Patients were selected from pro-
spectively maintained databases at the institutions and out-
comes of patients treated without or with chemotherapy
Table 3. Survival rates in patients with high-grade extremity soft tissue sarcoma treated with or without chemotherapy
Study Sarcoma type Chemotherapy
Disease-specific
survival rate
Eilber et al. (2007) [26] Synovial sarcoma Yes 4-yr, 88%
No 4-yr, 67%
Eilber et al. (2004) [27] Liposarcoma Yes 5-yr, 92%
No 5-yr, 65%
Grobmyer et al. (2004) [25] 5 cma Yes 3-yr, 79%
No 3-yr, 71%
10 cm Yes 3-yr, 83%
No 3-yr, 62%
DeLaney et al. (2003) [28] 8 cm Yes 5-yr, 87%b
No 5-yr, 58%b
aCourtesy of Stephen Grobmyer, M.D., and Elyn Riedel, M.A., Memorial Sloan-Kettering Cancer Center.
bOverall survival rate.
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were compared. Seventy-four patients received a mean of
three cycles of doxorubicin (75 mg/m2) and ifosfamide
(6 –9 g/m2) chemotherapy and 282 were treated without
chemotherapy. Even though patients were not randomized to
treatment, the groups were reasonably well balanced in tumor
site (upper versus lower extremity), histology (except for sy-
novial sarcoma), margin status, and follow-up interval. Pa-
tients treated with chemotherapy tended to be younger and
have larger tumors than patients not receiving chemotherapy.
The median follow-up at the time of the analysis was about 3
years. The disease-specific survival rate in patients treated
with chemotherapy was better than that in patients treated
without chemotherapy (the hazard ratio for effect of chemo-
therapy on survival was 0.52, a relative difference of about
50%). The beneficial effect of chemotherapy seemed to be
most pronounced in patients with sarcoma 10 cm in size and
seemed to be driven by a lower risk for distant metastasis in
the chemotherapy-treated than in the control population.
Patients with larger sarcomas receiving chemotherapy
had a 21% absolute survival benefit at 3 years, compared
with patients not receiving chemotherapy.
An analysis of patients with 5 cm, deep synovial sar-
coma localized to an extremity treated without or with che-
motherapy at Memorial Sloan-Kettering Cancer Center or
the University of California, Los Angeles, showed lower
rates of distant recurrence and death from synovial sarcoma
for patients receiving doxorubicin and ifosfamide chemo-
therapy in addition to local treatment than for patients re-
ceiving local therapy alone [26]. Similar to the analysis
discussed in the preceding paragraph, patient cases were
culled from prospectively maintained databases at the insti-
tutions. Chemotherapy using doxorubicin and ifosfamide
(n  31), doxorubicin, ifosfamide, and cisplatin (n  25),
or doxorubicin, ifosfamide, and dacarbazine (n  12) was
administered to 68 patients and no chemotherapy was ad-
ministered to 38 patients. Patients treated with chemother-
apy received a median of four cycles and a relatively high
median dose of ifosfamide of 12 g/m2 per cycle. The treat-
ment groups were well matched for patient age, tumor size,
histologic subtype, surgical procedure, and use of radiation.
More of the patients who did not receive chemotherapy had
microscopic positive surgical margins, but there was no dif-
ference in the local relapse rate between the groups. The du-
ration of follow-up for surviving patients was longer in the
control group. A multivariate analysis demonstrated that tu-
mor size and the use of chemotherapy were independently
associated with sarcoma-specific survival. The disease-
specific survival rate at 4 years was 88% for the patients re-
ceiving chemotherapy, compared with 67% for the patients
not receiving chemotherapy, a 21% greater absolute sur-
vival rate in the chemotherapy-treated group.
Patients with 5 cm, high-grade liposarcoma confined
to an extremity treated at Memorial Sloan-Kettering Cancer
Center or the University of California, Los Angeles, with
doxorubicin and ifosfamide were also shown to have a
lower risk for death from sarcoma than a contemporary co-
hort of patients treated without chemotherapy [27]. The
groups were balanced for histologic subtype (e.g., myxoid/
round cell, pleomorphic, and dedifferentiated). Patients re-
ceiving chemotherapy were younger and more likely to
have negative microscopic surgical margins. The median
follow-up interval was longer in the chemotherapy-treated
group. Multivariate analysis revealed that treatment using
chemotherapy, smaller tumor size, and myxoid/round cell
subtype were independently associated with longer sur-
vival. The 5-year sarcoma-specific survival rates for pa-
tients receiving versus not receiving chemotherapy were
92% and 65%, respectively, an absolute difference 25%.
DeLaney and colleagues at Massachusetts General Hos-
pital prospectively studied outcomes in patients with 8
cm, high-grade soft tissue sarcoma confined to an extremity
treated with doxorubicin, ifosfamide, and dacarbazine for
six cycles, radiation, and complete resection [28]. The first
three chemotherapy cycles were interdigitated with radia-
tion. More than 80% of the 48 patients studied were able to
complete six cycles of chemotherapy. Outcome was com-
pared with that of a contemporary cohort of patients
matched for tumor size, tumor grade, and patient age who
did not receive the protocol chemoradiotherapy. The rate of
local relapse was similar between groups, but the distant re-
lapse-free and survival rates were significantly better in the
group treated with chemoradiotherapy. The rates of dis-
ease-free and overall survival at 5 years for patients receiv-
ing the chemoradiation protocol versus the matched control
group were 70% versus 42% and 87% versus 58%, respec-
tively. Further study of the chemoradiotherapy protocol in a
broader cooperative group platform resulted in fewer pa-
tients completing the prescribed chemotherapy, more tox-
icity, and inferior outcomes [29]. The Massachusetts
General Hospital study was conducted by a multidisci-
plinary group of sarcoma specialists at one institution,
whereas the cooperative group study enrolled 66 patients
from 30 institutions. The poorer results from this regimen in
the cooperative group setting suggest that specialized expe-
rience with a complicated and potentially toxic treatment
protocol significantly affects outcome.
Cormier and colleagues performed a retrospective anal-
ysis that seems to refute the advantage from adjuvant che-
motherapy seen in the studies discussed above. They
reviewed the experience of 674 consecutive patients with
AJCC stage III extremity soft tissue sarcoma treated at the
MD Anderson Cancer Center and Memorial Sloan-Ketter-
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ing Cancer Center during a 15-year period and did not find
a sustained benefit from adjuvant chemotherapy [30]. The
nonrandomized comparison was balanced for tumor size,
patient sex, and quality of the surgical margin of the re-
sected sarcoma, but there were more patients in the che-
motherapy-treated group with “other” sarcomas (not
undifferentiated pleomorphic sarcoma/malignant fibrous
histiocytoma, liposarcoma, leiomyosarcoma, synovial sar-
coma, and undifferentiated sarcoma) and there were more
patients with liposarcoma in the “control” group, which
may have favored the group not treated with chemotherapy.
Overall, 18% of the patients had an “other” sarcoma his-
topathologic subtype. All the patients received doxorubi-
cin, but the dose intensity of the chemotherapy and the
percentage of patients receiving ifosfamide were not re-
ported. The median follow-up for surviving patients was 6
years and the disease-specific survival rate at 5 years was
61%. Analysis showed that the disease-specific survival
rate was higher during the first year for patients treated with
chemotherapy but was no different than for the control
group at 5 years. In this nonrandomized comparison, differ-
ent selection bias by the institutions occurred, with a major-
ity of patients at the MD Anderson Cancer Center and a
minority of patients at Memorial Sloan Kettering Cancer
Center receiving chemotherapy (MD Anderson patients not
receiving chemotherapy may have had a favorable progno-
sis and Memorial Sloan-Kettering patients treated with che-
motherapy may have had a poor prognosis). The authors
noted that comparisons of the subgroup of patients who sur-
vived 1 year should be interpreted with caution because
deaths occurring during the first year may have signifi-
cantly unbalanced the groups. The retrospective nature of
the analysis does not allow conclusions about the mecha-
nisms underlying the time-varying effects of chemotherapy
in this study to be drawn.
NEOADJUVANT CHEMOTHERAPY IN SOFT
TISSUE SARCOMA
Neoadjuvant chemotherapy in the treatment of localized
soft tissue sarcoma has been undertaken to assess sarcoma
response to therapy, initiate early treatment of microscopic
tumor metastasis, and improve local outcomes from sur-
gery, but only a few studies have analyzed relapse-free and
survival rates by primary tumor response. A complete or
near complete (95%) pathologic sarcoma response to pre-
operative chemotherapy and radiation, seen in about half of
the population studied, was independently associated with
lower local recurrence and better survival rates in patients
with extremity, high-grade soft tissue sarcoma [31]. The 5-
and 10-year survival rates for patients with a favorable
pathologic tumor response to preoperative therapy were
80% and 71%, respectively, compared with 62% and 55%,
respectively, in patients with a poorer tumor response.
Changes in extremity soft tissue sarcoma fluorodeoxyglu-
cose (FDG) uptake after preoperative chemotherapy may
also be predictive of long-term outcome. Patients with a
substantial decline in sarcoma FDG uptake measured by
positron emission tomography after chemotherapy had a
significantly lower risk for sarcoma recurrence and longer
survival than patients with little to no change in FDG uptake
[32]. The approximate 5-year recurrence-free and overall
survival rates for patients with a large decline in tumor FDG
uptake were 80% and 75%, respectively, compared with
35% and 35%, respectively, for patients with no significant
change in FDG uptake with chemotherapy. The relative risk
for dying from sarcoma was four times greater in the group
without than in the group with a sarcoma response to doxo-
rubicin-based chemotherapy. Patients with evidence of ra-
diographic or pathologic response of localized soft tissue
sarcoma to chemotherapy combined with regional hyper-
thermia also had a significantly higher survival rate than pa-
tients without a tumor response to preoperative therapy
[33]. Collectively, the reports suggest that patients with lo-
calized soft tissue sarcoma that respond to chemotherapy
with or without radiation seem to have a lower risk for re-
lapse and longer survival as a direct effect of chemotherapy
on undetected microscopic metastases. An alternative hy-
pothesis that tumor response to preoperative therapy is only
a prognostic marker for a lower risk for tumor metastasis
seems less plausible.
ADJUVANT CHEMOTHERAPY FOR CANCER
The use of adjuvant chemotherapy is an established stan-
dard practice for osteosarcoma, Ewing’s family of tumors,
and the pediatric rhabdomyosarcomas because of demon-
strably higher disease-free and overall survival rates in
randomized studies. Adjuvant chemotherapy in the man-
agement of localized, high-grade osteosarcoma was shown
to reduce relapse rates by 50% (from 80%–90% without
chemotherapy to 35%–45% with chemotherapy at 2 years)
and significantly improve survival to a substantial degree
[34, 35]. Because of the large difference in outcomes, a sig-
nificant benefit from adjuvant treatment was detected in the
very small study of 36 patients by Link et al. [35]. The ad-
dition of doxorubicin to a regimen of cyclophosphamide,
dactinomycin, and vincristine as adjuvant chemotherapy
for patients with localized Ewing’s sarcoma resulted in a
significantly higher 5-year survival rate, 60% versus 24%,
in a randomized trial of 222 patients, and thus became a
standard component of Ewing’s chemotherapy [36]. The
significant difference in outcomes between the groups (che-
motherapy versus no chemotherapy, doxorubicin versus no
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doxorubicin) could be readily demonstrated in relatively
small studies because of the large magnitude of the chemo-
therapy effect. More recently, the addition of ifosfamide
and etoposide to the standard chemotherapy backbone for
the treatment of patients with localized Ewing’s sarcoma
was shown to lead to a greater 5-year event-free survival
rate, 69% versus 54%, and greater overall survival rate,
72% versus 61% (an absolute difference of about 10%)
[37]. This more modest gain in survival was significant but
required a 400-patient trial based on the underlying pre-
study assumption that addition of ifosfamide and etoposide
would halve the failure rate within 3 years of follow-up.
Adjuvant chemotherapy is often employed in the manage-
ment of epithelial cancer for, at times, relatively small gains in
disease-free and overall survival. For example, in women 50
years of age with estrogen receptor–negative breast cancer, ad-
juvant chemotherapy reduces the risk for recurrence and death
at 10 years by about 10% and 6%, respectively [38]. This mod-
est improvement in survival is felt to be clinically relevant and
justify the 1%–2% risk for treatment-related mortality by the
National Comprehensive Cancer Network Breast Cancer
Committee, which recommends the use of adjuvant chemo-
therapy in the management of patients with estrogen receptor–
negative, node-negative invasive breast cancer 5 mm [39].
The statistical significance of small improvements in survival
with chemotherapy in breast cancer studies is aided by the in-
clusion of large numbers of patients. In the meta-analysis of
adjuvant chemotherapy in estrogen receptor–poor breast can-
cer, data from approximately 6,000 randomized patients were
analyzed [38]. The risk reduction in breast cancer patients
from adjuvant therapy of relatively small (5–20 mm) tumors is
similar to the risk reduction for sarcoma relapse and death
from adjuvant therapy in the sarcoma meta-analysis. A multi-
thousand patient randomized trial of adjuvant chemotherapy
in high-grade, primary soft tissue sarcoma is not likely to be
conducted, even with multinational collaboration, because of
the infrequency of the disease. The SMAC suggested that a
randomized trial of approximately 900 patients would be re-
quired to detect a 10% difference in overall survival with ad-
juvant chemotherapy; a trial to detect a 6% difference, as seen
in small, estrogen receptor–negative breast cancer, would re-
quire far in excess of 1,000 patients. The magnitude of benefit
from adjuvant chemotherapy in unselected soft tissue sarcoma
is likely to be relatively small, and large-scale randomized tri-
als of adjuvant chemotherapy in soft tissue sarcoma are un-
likely to be performed; therefore, “level 1” evidence to support
or refute the use of adjuvant chemotherapy is not likely to be
available. Recommendations for the use of adjuvant chemo-
therapy in localized soft tissue sarcoma should consider the
risk for disease relapse to the patient, the sarcoma histologic
subtype, and the available evidence from meta-analyses, small
randomized studies, and analyses of data from prospectively
maintained institutional databases.
CONCLUSIONS
Taking into account the facts discussed above and the negative
trials described in the companion manuscript by Drs. Blay and
Le Cesne [40], the answer to the question posed in the opening
statement of this manuscript is “yes.” We strongly feel that
there is “reasonable” evidence to support the use of more con-
temporary chemotherapy in selected patients with high-risk
localized soft tissue sarcomas. While we all anxiously await
molecularly targeted therapy with a much better therapeutic
index, it is our obligation to use the currently available agents
to the best of our ability to help patients who are presently in
our clinics. So how should the decision making proceed in the
clinic? In our opinion, patients with high-risk disease, defined
as 5 cm, high-grade, and deep soft tissue sarcomas, regard-
less of location, should be considered for adjuvant, or prefer-
ably neoadjuvant, systemic therapy. Patients who are
generally healthy, physiologically 65 years of age, with in-
tact organ function, including two functioning kidneys, should
be considered for a dose-intensive anthracycline and ifos-
famide combination with growth factor support. Individuals
who are older or have comorbidities resulting in a compromise
of performance status or organ function may still benefit from
anthracycline-based regimens, as shown by the SMAC data.
In selecting patients for adjuvant therapy, one also needs to
consider histologic subtypes. Those that have historically been
known to be resistant or poorly sensitive to conventional
agents (alveolar soft-part sarcomas, clear cell sarcomas, he-
mangiopericytomas, extraskeletal myxoid chondrosarcomas,
epithelioid sarcomas, etc.) should be excluded, and those pa-
tients should be spared the unnecessary toxicities of the regi-
men. Although such an approach has been criticized in the past
for patient selection, we would submit that this in fact repre-
sents good clinical judgment—something we all are trained in
and should use in day-to-day routine practice. The lessons
learned from historic gastrointestinal leiomyosarcomas being
insensitive to conventional chemotherapeutic agents yet al-
ways included in large randomized trials to be “inclusive” and
now the clear recognition that this is a unique entity redefined
as gastrointestinal stromal tumor should serve as the basis for
personalizing therapy. This complex group of diverse diseases
that, for simplicity, we identify as soft tissue sarcomas cer-
tainly is not one uniform disease entity. As for the question of
the preoperative versus postoperative use of adjuvant chemo-
therapy, again, lessons learned from the osteosarcoma experi-
ence teach us that when chemotherapy is indicated and
planned, it makes infinitely greater sense to use it with disease
in place to serve as a marker and an in vivo test of the efficacy
of the toxic and marginally effective chemotherapy.
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So, in conclusion, acknowledging the data, the variable in-
terpretation, and personal physician bias on both sides of the
aisle as outlined in these companion manuscripts, added to the
irrefutable fact that an appropriately powered, randomized, ad-
juvant therapy trial in uniform subsets of patients with cur-
rently available agents is unlikely to happen, we should use the
available agents and information to best serve the patients for
which we care. We therefore recommend that systemic ther-
apy with an anthracycline or anthracycline and ifosfamide
combination should be considered, preferably preoperatively,
in appropriately selected patients with soft tissue sarcoma that
are at a high risk for recurrence and/or metastases. Such inter-
ventions are always preferable in clinical trials attempting to
either improve efficacy or attenuate toxicities or both. With re-
cent advances in molecular biology resulting in the identifica-
tion of specific targets and in light of the classic and enviable
example of imatinib in gastrointestinal stromal tumor, we re-
main quite optimistic that significant progress is likely to be
made in the foreseeable future and hope that new treatments
may well make this current debate moot.
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